Relay Therapeutics Stock Performance
| RLAY Stock | USD 3.63 0.03 0.83% |
Relay Therapeutics holds a performance score of 17 on a scale of zero to a hundred. The company holds a Beta of 1.88, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Relay Therapeutics will likely underperform. Use Relay Therapeutics value at risk, as well as the relationship between the kurtosis and market facilitation index , to analyze future returns on Relay Therapeutics.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Relay Therapeutics are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. In spite of fairly conflicting basic indicators, Relay Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Disposition of 18653 shares by Patel Sanjiv of Relay Therapeutics at 2.97 subject to Rule 16b-3 | 04/23/2025 |
2 | Top Executive Makes Significant Move with Relay Therapeutics Stock - TipRanks | 04/24/2025 |
3 | Disposition of 3558 shares by Thomas Catinazzo of Relay Therapeutics at 3.23 subject to Rule 16b-3 | 04/29/2025 |
4 | Transcript Relay Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 03 - marketscreener.com | 05/14/2025 |
5 | What Makes Relay Therapeutics a New Buy Stock | 05/23/2025 |
6 | Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June RLAY Stock News | 05/29/2025 |
7 | Relay Therapeutics Announces Updated Data for RLY-2608 Fulvestrant Further Demonstrating ... | 06/02/2025 |
8 | Relay Therapeutics Gets a Hold from Wells Fargo - The Globe and Mail | 06/05/2025 |
9 | Acquisition by Rubin Jami of 136681 shares of Relay Therapeutics at 3.36 subject to Rule 16b-3 | 06/06/2025 |
10 | Relay Therapeutics, Inc. A Bull Case Theory | 06/09/2025 |
11 | Disposition of 12943 shares by Adams Brian of Relay Therapeutics at 3.0 subject to Rule 16b-3 | 06/20/2025 |
12 | BofA Reiterates a Buy Rating on Relay Therapeutics , Sets a 17 PT | 06/24/2025 |
| Begin Period Cash Flow | 146.4 M |
Relay Therapeutics Relative Risk vs. Return Landscape
If you would invest 205.00 in Relay Therapeutics on April 6, 2025 and sell it today you would earn a total of 158.00 from holding Relay Therapeutics or generate 77.07% return on investment over 90 days. Relay Therapeutics is currently generating 1.0236% in daily expected returns and assumes 4.4897% risk (volatility on return distribution) over the 90 days horizon. In different words, 40% of stocks are less volatile than Relay, and 80% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Relay Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Relay Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Relay Therapeutics, and traders can use it to determine the average amount a Relay Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.228
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | RLAY | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.49 actual daily | 40 60% of assets are more volatile |
Expected Return
| 1.02 actual daily | 20 80% of assets have higher returns |
Risk-Adjusted Return
| 0.23 actual daily | 17 83% of assets perform better |
Based on monthly moving average Relay Therapeutics is performing at about 17% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Relay Therapeutics by adding it to a well-diversified portfolio.
Relay Therapeutics Fundamentals Growth
Relay Stock prices reflect investors' perceptions of the future prospects and financial health of Relay Therapeutics, and Relay Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Relay Stock performance.
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (11.05) % | ||||
| Current Valuation | (40.85 M) | ||||
| Shares Outstanding | 171.44 M | ||||
| Price To Book | 0.86 X | ||||
| Price To Sales | 81.05 X | ||||
| Revenue | 10.01 M | ||||
| Gross Profit | (299.17 M) | ||||
| EBITDA | (372.47 M) | ||||
| Net Income | (337.71 M) | ||||
| Cash And Equivalents | 1.05 B | ||||
| Cash Per Share | 8.72 X | ||||
| Total Debt | 48.5 M | ||||
| Debt To Equity | 0.06 % | ||||
| Book Value Per Share | 4.23 X | ||||
| Cash Flow From Operations | (249.11 M) | ||||
| Earnings Per Share | (2.20) X | ||||
| Total Asset | 871.3 M | ||||
| Retained Earnings | (1.74 B) | ||||
About Relay Therapeutics Performance
Evaluating Relay Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Relay Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Relay Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Relay Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 320 people.Things to note about Relay Therapeutics performance evaluation
Checking the ongoing alerts about Relay Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Relay Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Relay Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 10.01 M. Net Loss for the year was (337.71 M) with loss before overhead, payroll, taxes, and interest of (299.17 M). | |
| Relay Therapeutics currently holds about 1.05 B in cash with (249.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.72, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Relay Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from insidermonkey.com: BofA Reiterates a Buy Rating on Relay Therapeutics , Sets a 17 PT |
- Analyzing Relay Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Relay Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Relay Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Relay Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Relay Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Relay Therapeutics' stock. These opinions can provide insight into Relay Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Relay Stock Analysis
When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.